Evidence map›Paper›PMID 34887451›Full record

ReviewNature reviews. Disease primers2021

Endometrial cancer.

Vicky Makker, Helen MacKay, Isabelle Ray-Coquard, Douglas A Levine, Shannon N Westin, Daisuke Aoki, Ana Oaknin

2 registry-linked trialsAbstract readReview
In one paragraph

Review in Nature reviews. Disease primers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 420 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
420citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06306170 recruitingnot on this mapstarted 2024, after this paper: background citation

Efficacy of Advanced Radiotherapy (ART) in Gynecological Cancer Patients (GYN-ART)

TypeobservationalSponsorIRCCS San RaffaeleRan2024 to 2029Enrolled1,000ConditionsGynecologic Cancer, Radiotherapy Side Effect, Radiotherapy, ComplicationsArmsImage Guided Radiotherapy
NCT07339384 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Circulating Tumor DNA Assessment in Early-Stage Endometrial Cancer (SIGNAL-EMC 101)

TypeinterventionalSponsorNatera, Inc.Ran2026 to 2034Enrolled1,010ConditionsEndometrial CancerArmsSignatera Genome ultra-sensitive ctDNA blood test
3 · Its place in the literature

Who cites it

420 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Establishment of insulin resistance-related ten-gene signature in endometrial cancer and identification of ACTL8 as a prognostic and immunological biomarker.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Article

360 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Vicky MakkerGynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. makkerv@mskcc.org.ORCID http://orcid.org/0000-0001-9793-7614
Helen MacKayUniversity of Toronto, Division of Medical Oncology & Hematology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada.
Isabelle Ray-CoquardDepartment of Medical Oncology, Centre Leon Berard, Laboratoire Reshape University Claude Bernard Lyon, Lyon, France.ORCID http://orcid.org/0000-0003-2472-8306
Douglas A LevineLaura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
Shannon N WestinDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1922-0156
Daisuke AokiDepartment of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Ana OakninGynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID http://orcid.org/0000-0002-3592-7194

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI FRANCESCA M GANY · 1985 to 2026
$347.4M
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Kathrin Milbury · 1985 to 2026
$290.8M
Targeting the PI3K Signaling Pathway in Endometrial CarcinomaP50CA098258 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YUAN, YING · 2003 to 2020
$32.0M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA098258
6 · The paper itself

Abstract

Although endometrial cancer management remains challenging, a deeper understanding of the genetic diversity as well as the drivers of the various pathogenic states of this disease has led to development of divergent management approaches in an effort to improve therapeutic precision in this complex malignancy. This comprehensive review provides an update on the epidemiology, pathophysiology, diagnosis and molecular classification, recent advancements in disease management, as well as important patient quality-of-life considerations and emerging developments in the rapidly evolving therapeutic landscape of endometrial cancers.

Indexed as

Endometrial NeoplasmsFemaleHumans

Identifiers

PMID34887451
PMCPMC9421940

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.